Dr Masoud Mardani Prof of Infectious Diseases Shahid ... › DL › seminar ›...
Transcript of Dr Masoud Mardani Prof of Infectious Diseases Shahid ... › DL › seminar ›...
Dr Masoud Mardani Prof of Infectious Diseases Shahid Beheshti University
updated its recommendations for the use
of influenza antiviral medicines
September 8, 2009 CDC
It is to prioritize use of these drugs for those patients
who are severely ill (hospitalized) and those patients with influenza-like illness and who are at high risk for influenza related complications.
limited situations in which antiviral medications should be used for chemoprophylaxis (prevention) this season.
The antiviral drugs should not be used for prevention in healthy persons based on community exposures.
Most people ill with influenza will recover without complications.
Some people are at increased risk of influenza complications and are prioritized for treatment with influenza antiviral drugs this season. They include:
People hospitalized with suspected or confirmed influenza
People with suspected or confirmed influenza who are at higher risk for complications • Children younger than 5 years old (children under 2
years old are at higher risk for complications than older children)
• Adults 65 years and older
• Pregnant women
• People with certain chronic medical or immunosuppressive conditions
People younger than 19 years of age who are receiving long-term aspirin therapy .
Treatment with influenza antiviral drugs is generally not needed for people who are not at higher risk for complications or do not have severe influenza, such as those requiring hospitalization.
However, any suspected influenza patient who presents with emergency warning signs (for example, difficulty breathing or shortness of breath) or signs of lower respiratory tract illness should promptly receive antiviral therapy
oseltamivir (trade name Tamiflu®)
or zanamivir (trade name Relenza®)
Or Peramivir which recently authorized
for IV use in emergency set up
is recommended for all people with
suspected or confirmed flu who require
hospitalization.
antiviral drugs should be started within 2 days after becoming sick.
These drugs can reduce the severity of flu symptoms and shorten the time you are sick by 1 or 2 days.
They may also prevent serious flu
complications.
Antiviral drugs may be especially important for people who are very sick (hospitalized) with the flu and who are at increased risk of serious flu complications, such as pregnant women, young children and those with chronic health conditions.
antiviral drugs are about 70% to 90%
effective against susceptible viruses (i.e.,
viruses that are not resistant to the
antiviral medication).
It’s important to remember that flu
antiviral drugs are not a substitute for
getting a flu vaccine
Even for patients whose treatment was started
more than 48 hours after illness onset.
When treatment is indicated, health care providers
generally should not wait for laboratory
confirmation of influenza to begin treatment with
antiviral drugs because laboratory testing can
delay treatment and because a negative rapid test
for influenza does not rule out influenza.
The sensitivity of rapid influenza diagnostic tests
can range from 10-70% for 2009 H1N1 virus.
Groups at higher risk for influenza related complications are similar to those at higher risk for seasonal influenza complications and include: children younger than 5 years old;
adults 65 years of age and older, pregnant women, people of any age with certain chronic medical
conditions (for example, asthma, diabetes, lung disease, people with weakened immune systems, etc.) and people younger than 19 years of age who are receiving long-term aspirin therapy.
The recommended duration of treatment
is five days.
However, hospitalized patients with
severe infections might require longer
treatment courses.
occupational risk for exposure (health care personnel, public health workers, or first responders who are working in communities with influenza A H1N1 outbreak), especially those at higher risk for complications of influenza, should carefully follow guidelines for appropriate personal protective equipment to prevent influenza exposure to influenza.
Antiviral chemoprophylaxis generally
should be reserved for people at higher
risk for influenza-related complications
who have had contact with someone
likely to have been infected with
influenza.
health care personnel, public health workers, or first responders who have had a recognized, unprotected close contact exposure to a person with confirmed, probable, or suspected 2009 H1N1 or seasonal influenza during that person’s infectious period.
However, use of recommended PPE and other administrative controls (e.g. having health care personnel stay home from work when ill, and triaging for identification of potentially infectious patients) should be used
there are no safety data regarding long
term or frequent use of antiviral agents in
children, and limited data for healthy
adults
Duration of antiviral chemoprophylaxis
post-exposure is 10 days after the last
known exposure
The preferred treatment of pregnant women, Oseltamivir and zanamivir are "Pregnancy Category C" medications, indicating that no clinical studies have been conducted to assess the safety of these medications for pregnant women.
Pregnancy should not be considered a contraindication to oseltamivir or zanamivir use. Because of its systemic activity.
Side effects differ for each drug.
If an antiviral drug has been prescribed
for you, ask your doctor to explain how to
use the drug and any possible side
effects.
Health care professionals prescribing flu
antiviral drugs should alert patients
about adverse events that can occur.
Yes. CDC and ACIP recommend use of
antiviral drugs for people allergic to
eggs (which can cause them to have an
allergic reaction to the vaccine)
or for people who previously have
encountered complications from
Guillain-Barre syndrome (GBS)
associated with influenza vaccination.
The seasonal flu vaccine is unlikely to
provide protection against 2009 H1N1
influenza.
However a 2009 H1N1 vaccine is
currently in production and it is ready
for the public in the fall.
The 2009 H1N1 vaccine is not intended to
replace the seasonal flu vaccine – it is
intended to be used along-side seasonal
flu vaccine.
Pregnant women because they are at higher risk of complications and can potentially provide protection to infants who cannot be vaccinated;
Household contacts and caregivers for children younger than 6 months of age because younger infants are at higher risk of influenza-related complications and cannot be vaccinated. Vaccination of those in close contact with infants younger than 6 months old might help protect infants by “cocooning” them from the virus;
Healthcare and emergency medical
services personnel because infections
among healthcare workers have been
reported and this can be a potential
source of infection for vulnerable
patients. Also, increased absenteeism in
this population could reduce healthcare
system capacity;
All people from 6 months through 24 years of age • Children from 6 months through 18 years of age
because cases of 2009 H1N1 influenza have been seen in children who are in close contact with each other in school and day care settings, which increases the likelihood of disease spread, and
• Young adults 19 through 24 years of age because many cases of 2009 H1N1 influenza have been seen in these healthy young adults and they often live, work, and study in close proximity, and they are a frequently mobile population; and,
Once the demand for vaccine for the
prioritized groups has been met at the local
level, programs and providers should also
begin vaccinating everyone from the ages of 25
through 64 years.
Persons aged 25 through 64 years who have
health conditions associated with higher
risk of medical complications from
influenza
Current studies indicate that the risk for
infection among persons age 65 or older is less than the risk for younger age groups.
However, once vaccine demand among younger age groups has been met, programs and providers should offer vaccination to people 65 or older.
Swine Influenza (swine flu) is a respiratory disease of pigs caused by type A influenza virus that regularly causes outbreaks of influenza in pigs .
most outbreaks occur during the late fall and winter months similar to outbreaks in humans .
The classical swine flu virus (an influenza type A H1N1 virus) was first isolated from a pig in 1930
25%-30% of world’s
population (~500
million people) fell ill
>40 million deaths
worldwide; ~60% in
people ages 20-45
>500,000 deaths in
United States; 196,000
in October, 1918
alone
Influenza
Pandemic
of 1918-19
Hemagglutinin
Neuraminidase
Influenza Virus
Drift
Shift
Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. N Engl J Med 2009;10.1056/NEJMoa0903810
Comparison of H1N1 Swine Genotypes in Recent Cases in the United States
like seasonal flu, symptoms of swine flu infections can include:
fever, which is usually high, but unlike seasonal flu, is sometimes absent
cough runny nose or stuffy nose sore throat body aches headache chills fatigue or tiredness, which can be extreme diarrhea and vomiting, sometimes, but more commonly seen
than with seasonal flu
Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. N Engl J Med 2009;10.1056/NEJMoa0903810
Characteristics and Symptoms of the 642 Patients with Confirmed Swine-Origin Influenza A (H1N1)
Signs of a more serious swine flu
infection might include;
pneumonia and
Rapidly Progressive Pneumonia
respiratory failure.
With regular seasonal flu, infants and the
elderly are usually thought to be most at
risk for serious infections, in addition to
people with chronic medical problems.
Swine flu high risk groups, people who
are thought to be at risk for serious, life-
threatening infections, are a little
different and can include:
pregnant women
people with chronic medical problems,
such as chronic lung disease, like asthma,
cardiovascular disease, diabetes, and
immunosuppression
children and adults with obesity
More serious symptoms that
would indicate that a child with
swine flu would need urgent
medical attention
Fast breathing or trouble breathing
Bluish or gray skin color
Not drinking enough fluids
Severe or persistent vomiting
Not waking up or not interacting
Being so irritable that the child does not
want to be held
Flu-like symptoms improve but then
return with fever and worse cough
spring allergies - runny nose, congestion, and cough
common cold - runny nose, cough, and low grade fever
sinus infections - lingering runny nose, cough, and fever
strep throat - sore throat, fever, and a positive strep test
A respiratory specimen would generally need to be
collected within the first 4 to 5 days of illness (when an
infected person is most likely to be shedding virus .)
However, some persons, especially children, may shed virus
for 10 days or longer .
Identification as a swine flu influenza A virus requires
sending the specimen to Refference laboratory testing .
A respiratory specimen would generally need to be
collected within the first 4 to 5 days of illness (when an
infected person is most likely to be shedding virus .)
However, some persons, especially children, may shed virus
for 10 days or longer .
Identification as a swine flu influenza A virus requires
sending the specimen to Refference laboratory testing .
There are four different antiviral drugs that are licensed for use for the treatment of influenza: amantadine, rimantadine, oseltamivir and zanamivir .
The most recent swine influenza viruses isolated from humans are resistant to amantadine and rimantadine.
At this time, CDC recommends the use of oseltamivir or zanamivir for the treatment and/or prevention of infection with swine influenza viruses.
Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. N Engl J Med 2009;10.1056/NEJMoa0903810
Characteristics and Symptoms of the 642 Patients with Confirmed Swine-Origin Influenza A (H1N1)
Neuraminidase (NA)
Matrix protein (M2 )
M2 Inhibitors
• Amantadine
• Rimantadine
NA Inhibitors
• Oseltamivir
• Zanamivir
Efficacy
(vs placebo or no drug)
Strategy AM/RM ZNV OSEL
Seasonal
Non-immunized adults 85%-91% 84%1 84%
Immunized NH elderly 58%-75% ? 92%
Post-contact/Post-exposure
Households 3%-100% 82%3 67%-89%2
Nursing homes Variable 61%4 Yes5
1. Monto A et al. JAMA. 1999;282:31. 2. Hayden F et al. N Engl J Med. 1999; 341:1336. 3. Hayden F et al. N Engl J Med. 2000;343:12882. 4. Gravenstein S et al. J Am Med Dir Assoc. 2005;6:359. 5. Peters P et al. J Am Gerontol Soc. 2001;404:1025.
Amantadine* Rimantadine* Zanamivir Oseltamivir
Protein
target M2 M2 NA NA
Activity A only A only A and B A and B
Therapy
Adults and
children of
1 year
Adults
only
Adults and
children of
5 years
Adults and
children of
1 year
Prophylaxis Yes Yes
Adults and
children of
7 years
Yes
Treanor J. Influenza Virus. In Mandell, Douglas, and Bennett's Principles and Practice of Infectious diseases. 6th ed. New York: Elsevier/Churchill Livingstone; 2005:2072. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01341.html.
*CDC recommends that the previously approved M2 inhibitors amantadine (Symmetrel) and rimantadine
(Flumadine) not be used for the treatment or chemoprophylaxis of influenza A infections in the United
States for the remainder of the 2005-2006 season (CDC. MMWR Dispatch. January 17, 2006).
Antiviral Agent Age Groups (years)
1-5
>5
Oseltamivir
Treatment By weight 75 mg BID
Prophylaxis By weight 75 mg QD
Zanamivir
Treatment* 10 mg (2 inhalations) QD 10 mg (2 inhalations)
QD
Prophylaxis* 10 mg (2 inhalations) QD 10 mg (2 inhalations)
QD
CDC recommends that the previously approved M2 inhibitors amantadine (Symmetrel) and
rimantadine (Flumadine) not be used for the treatment or chemoprophylaxis of influenza A
infections in the United States for the remainder of the 2005-2006 season
*Zanamivir approved for treatment in children >7 years, for prophylaxis in children >5 years
0
20
40
60
80
100
120
Influenza Infected Intent toTreat
Ho
urs
Placebo Oseltamivir 75 mg BID
Difference = 32 hours*
*P < .001 †P = .004
Treanor J et al. JAMA. 2000;283:1016-1024.
Difference = 21 hours†
Placebo Oseltamivir % Reduction
Hospitalizations
Healthy adults 5/662 (0.8%) 3/982 (0.3%)
High-risk + elderly 13/401 (3.2%) 6/368 (1.6%)
Total 18/1063 (1.7%) 9/1350 (0.7%) 59%*
Lower Respiratory Tract Complications Leading to Antibiotic Use
Healthy adults 35/662 (5.3%) 17/982 (1.7%)
High-risk + elderly 78/401 (18.5%) 45/368 (12.2%)
Total 109/1063 (10.3%) 62/1350 (4.6%) 55%†
*P = .02; †P < .001
Setting Resistance Reported/
Number Patients Rate of
Emergence
Adult trials 1/350 <<1%
US pediatric trial 5/147 4%
Japanese children 7/43 16%
Japanese children 9/50 18%
Kaiser L et al. Arch Intern Med. 2003;163:1667-1672. Whitley R et al. Pediatr Infect Dis J. 2001;20:127-133. Kiso M et al. Lancet. 2004;364:759-765.
Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. N Engl J Med 2009;10.1056/NEJMoa0903810
Susceptibility of 37 Isolates of Swine-Origin Influenza A (H1N1) Virus to Neuraminidase Inhibitors
Health Status Activity Level
0
12
8
6
4
2
Placebo (n = 129)
Oseltamivir 75 mg BID (n = 124)
10
Placebo (n = 129)
Oseltamivir 75 mg BID (n = 124)
Days
*P < .001 †P = .02
Treanor J et al. JAMA. 2000;283:1016-1024.
Difference = 1.9 days* Difference = 2.8 days†
Resistance not recorded in results from clinical trials1, 2, 3
The only zanamivir-resistant mutant identified was in a virus from an immunocompromised child4
Particular binding mechanisms may account for low levels of resistance to zanamivir5, 6
Particular mutants are resistant to zanamivir in vitro7, 8
1. Monto A et al. Antimicrob Agents Chemother. 2006;50:2395-2402.
2. Ambrozaitis A et al. J Am Med Dir Assoc. 2005;6:367-374.
3. Herlocher M et al. J Infect Dis. 2003;188:1355-1361.
4. Gubareva L et al. J Infect Dis. 1998;178:1257-1262.
5. Moscona A. N Engl J Med. 2005;353:2633-2636.
6. Gupta R and Nguyen-Van-Tam J. N Engl J Med. 2006;354:1423-1424.
7. Yen H et al. Antimicrob Agents Chemother. 2005;49:4075-4084.
8. Mishin V et al. Antimicrob Agents Chemother. 2005;49:4515-4520.
Flu symptoms in school-age children and adolescents are similar to those in adults
• Temperature of 101°F or above, cough, muscle ache,
headache, sore throat, chills, fatigue, general malaise
• Public advised to contact physician for these symptoms
Children tend to have higher temperatures than adults, ranging from 103°F to 105°F
Flu in preschool children and infants is hard to pinpoint, since its symptoms are so similar to infections caused by other viruses
Immunocompromised patients suffer more complications and have higher morbidity and mortality from influenza infection
• High rate of hospitalization and ICU admissions
• Higher rate of pulmonary complications
50% of BMT and 13% renal transplant patients had lower respiratory tract infections
50% of BMT and 7% of renal transplant patients with influenza complicated by pneumonia
63% progressed to pneumonia
43% mortality
http://www.shea-online.org/Assets/files/W_-_Seasonal_and_Pandemic_Influenza_-
_Children__Immunocompromised_Hosts__Pregnant_Women__and_Nursing_Home_Residents.ppt.
0
20
40
60
80
100
120
Not
Pregnant
1 to 13 14 to 26 27 to 42 Postpartum
Non-influenza Peri-influenza Influenza
Neuzil K et al. Am J Epidemiol. 1998;148:1094-1102.
Influenza In Pregnant Women E
vents
per
10,0
00
wom
en-m
onth
s
Pregnancy Status (Weeks) *November 1-April 30
period with no influenza
activity
*
Seasonal
Influenza
Preparedness
Pandemic
Influenza
Preparedness